查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1542884

全球截瘫市场 BCI（脑机介面） - 2024-2031

Global BCI (Brain-Computer Interfaces) in Paraplegia Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

截瘫市场的全球BCI（脑机介面）市场在2023年达到2.385亿美元，预计到2031年将达到3.462亿美元，在2024-2031年预测期间复合年增长率为4.2%。

脑机介面是实现大脑与外部输出之间直接通讯的系统。这些 BCI 设备由感测器组成，这些感测器测量神经元的电生理学并将讯息转发到外部设备，例如电脑、机器人肢体或嵌入处理大脑讯号的软体的任何其他外部系统。简而言之，脑机介面允许使用者透过思维来控制设备。目前，许多神经技术公司正在积极测试这些设备，以将其投入临床使用。对于截瘫患者来说，脑机介面将提供移动、执行常规任务并提高其整体生活品质的机会。

市场动态：

司机

投资和研发活动不断增加

用于截瘫患者的 BCI（脑机介面）设备仍在开发中。多家神经科技公司正在努力将 BCI 设备投入临床使用，其中一些公司已获得监管机构的批准，可以在人体上进行测试。随着力度不断加大，预计该市场将以最高增速成长。

例如，2021年4月，IpsiHand成为第一个获得美国食品药物管理局（FDA）核准用于临床的脑机介面产品。由 Neuroloutions, Inc. 开发的 IpsiHand 适用于上肢慢性中风患者的復健。该设备可在家庭和诊所环境中使用。

继 4 月 IpsiHand 获得批准后，美国 FDA 已指定 Blackrock Neurotech 的 MoveAgain 脑机介面系统为突破性设备，用于行动障碍患者。借助此 BCI 系统，患者将能够控制电脑、手机和轮椅。

一些这样的公司正在积极对其 BCI 发明进行调查研究。例如，马斯克 (Elon Musk) 经营的 Neuralink 公司在今年年初将其专有的 BCI 设备植入了第一位患者体内。 PRIME 研究旨在评估瘫痪患者用意念控制外部设备的设备的安全性和功能性。

这些突破性的创新预计将在不久的将来彻底改变截瘫患者的治疗方法。

例如，

限制

截瘫患者的 BCI（脑机介面）市场受到多种因素的限制，例如缺乏足够的批准用于临床的产品、批准产品的高成本、高开发成本以及患者群体中的技术模糊性。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

  • 影响因素
    • 司机
      • 投资和研发活动不断增加
      • 截瘫治疗技术的采用不断增加
    • 限制
      • 缺乏临床核准的设备
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 未满足的需求
  • PESTEL分析
  • 专利分析
  • SWOT分析

第 6 章：按类型

  • 侵入性
  • 微创
  • 非侵入性

第 7 章：按技术

  • 微电极阵列 (MEA)
  • 皮质电图（EcoG）
  • 脑电图仪（EEG）
  • 功能近红外光光谱 (fNIRS)
  • 其他的

第 8 章：按申请

  • 行动协助
  • 沟通
  • 復健治疗
  • 其他的

第 9 章：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 10 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 11 章：公司简介

  • Neurolutions, Inc.
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Synchron
  • Neuralink
  • Blackrock Neurotech.
  • BrainGate.
  • Paradromics.
  • Cognixion
  • EMOTIV
  • Precision Neuroscience
  • Bitbrain Technologies

第 12 章：附录

简介目录
Product Code: MD8600

Overview

The global BCI (brain-computer interfaces) in paraplegia market reached US$ 238.5 million in 2023 and is expected to reach US$ 346.2 million by 2031, growing at a CAGR of 4.2% during the forecast period 2024-2031.

Brain-computer interfaces are the systems that enable direct communication between the brain and the external output. These BCI devices consist of sensors that measure the electrophysiology of neurons and relay the information to an external device such as a computer, robotic limb, or any other external system embedded with software that processes the brain signals. In short, brain-computer interfaces allow the users to control devices by thinking. At present, many of the neurotechnology firms are actively testing these devices to bring them to clinical use. For paraplegic patients, brain-computer interfaces will provide an opportunity to move, perform regular tasks, and improve their overall quality of life.

Market Dynamics: Drivers

Rising investments and R&D activities

BCI (brain-computer interface) devices for paraplegia patients are still under development. Several neurotech companies are striving to bring BCI devices to clinical use, and some of these companies have received approval from the regulatory bodies to test on human subjects. As the efforts continue to rise, the market is anticipated to grow with the highest growth rate.

For instance, in April 2021, IpsiHand became the first brain-computer interface product to be approved for clinical use by the U.S. Food and Drug Administration (FDA). IpsiHand developed by Neuroloutions, Inc. is indicated for rehabilitation of upper extremity chronic stroke patients. The device can be used in home and clinic settings.

Followed by IpsiHand approval in April, the USFDA has designated Blackrock Neurotech's MoveAgain Brain-Computer Interface System Receives as a Breakthrough Device for use in patients with moving disability. With this BCI system, the patient will be able to control a computer, mobile, and wheelchair.

Several such companies are actively conducting investigational studies for their BCI inventions. For instance, Neuralink the Elon Musk-run company implanted their propreitory BCI device in their first patient early this year. The PRIME study aimed to evaluate the safety and functionality of the device in patients with paralysis to control external devices with their thoughts.

These groundbreaking innovations are anticipated to revolutionize the therapy for paraplegia patients in the near future.

For instance,

Restraints

The market for BCI (brain-computer interfaces) in paraplegia is restrained by several factors such as the lack of sufficient approved products for clinical use, the high cost of approved products, high development costs, and technology ambiguity in the patient population.

Segment Analysis

The global BCI (brain-computer interfaces) in paraplegia market is segmented based on type, technology, application, and region.

Electroencephalograph (EEG) in the technology segment accounted for approximately 43.7% of the global BCI (brain-computer interfaces) in paraplegia market share

The current technology that is being widely adopted for brain-computer interface development is electroencephalography (EEG). This has become an integral technology for the BCI systems due to its non-invasive nature which collects the neural signals. Moreover, it offers a cost-effective solution for the developer and to the patient, without any devoid of accuracy.

At present, the major companies that are actively developing BCI systems are focusing on EEG technology. For instance, the FDA-approved BCI device IpsiHand, uses an EEG headset to record the brain signals and control the movement produced in devices attached to extremities. Moreover, the BCI system developed by Cognixion uses EEG as a major recording technology in their devices. The devices by EMOTIV, another leading developer in this neurotech industry are employing EEG technology. Hence, the market for this technology is anticipated to have a significant growth rate in the forecast period.

Geographical Analysis

North America is expected to dominate the market with a share of 49.5% in the global BCI (brain-computer interfaces) in paraplegia market.

The North American region is expected to dominate the market due to its well-advanced healthcare infrastructure, and higher investments by market players supported by regulatory bodies for innovations. Moreover, the approved BCI systems in the current market are only available in the region, especially in the United States. For instance, IpsiHand is currently available for U.S. citizens with moving disabilities on a prescription basis.

The Neuralink BCI system is currently being clinically evaluated in the U.S., which means, the the device if found successful, will be made available first to U.S. paraplegia patients.

In addition, as the prevalence of paralysis is higher in the U.S., the opportunity for market players to develop their innovation is also high in the region. For instance, according to a study conducted by the Christopher & Dana Reeve Foundation in 2022, approximately 17 people are suffering from some kind of stroke per 1000 population in the U.S. which makes a total prevalence of 5.78 million patients in 2023.

Hence considering all these factors, North America is expected to dominate the market and experience significant growth in the forecast period. The region also projects itself as a major hub for investments in this novel neurotech market.

Market Segmentation

By Type

  • Invasive
  • Minimally Invasive
  • Non-Invasive

By Technology

  • Microelectrode Array (MEA)
  • Electrocorticography (EcoG)
  • Electroencephalograph (EEG)
  • Functional Near Infrared Spectroscopy (fNIRS)
  • Others

By Application

  • Mobility Assistance
  • Communication
  • Rehabilitation
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major players in the BCI (brain-computer interfaces) in paraplegia market include Neurolutions, Inc., Synchron, Neuralink, Blackrock Neurotech., BrainGate., Paradromics., Cognixion, EMOTIV, Precision Neuroscience, and Bitbrain Technologies among others.

Why Purchase the Report?

  • To visualize the global BCI (brain-computer interfaces) in paraplegia market segmentation based on type, technology, application, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of BCI (brain-computer interfaces) in paraplegia market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global BCI (brain-computer interfaces) in paraplegia market report would provide approximately 62 tables, 55 figures, and 187 Pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Application

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising investments and R&D activities
      • 4.1.1.2. Rising technology adoption for the treatment of paraplegia
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of clinically approved devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs
  • 5.6. PESTEL Analysis
  • 5.7. Patent Analysis
  • 5.8. SWOT Analysis

6. By Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. Invasive*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Minimally Invasive
  • 6.4. Non-Invasive

7. By Technology

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 7.1.2. Market Attractiveness Index, By Technology
  • 7.2. Microelectrode Array (MEA)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Electrocorticography (EcoG)
  • 7.4. Electroencephalograph (EEG)
  • 7.5. Functional Near Infrared Spectroscopy (fNIRS)
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Mobility Assistance*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Communication
  • 8.4. Rehabilitation
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
      • 9.3.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.2. Germany
      • 9.3.5.3. UK
      • 9.3.5.4. France
      • 9.3.5.5. Italy
      • 9.3.5.6. Spain
      • 9.3.5.7. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
      • 9.4.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.2. Brazil
      • 9.4.5.3. Argentina
      • 9.4.5.4. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
      • 9.5.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.2. China
      • 9.5.5.3. India
      • 9.5.5.4. Japan
      • 9.5.5.5. South Korea
      • 9.5.5.6. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Neurolutions, Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Synchron
  • 11.3. Neuralink
  • 11.4. Blackrock Neurotech.
  • 11.5. BrainGate.
  • 11.6. Paradromics.
  • 11.7. Cognixion
  • 11.8. EMOTIV
  • 11.9. Precision Neuroscience
  • 11.10. Bitbrain Technologies

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us